MedTrace Logo

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-02-11

No results posted yet for this study

Summary

The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma Grade 3B
  • High-grade B-cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma

Interventions

BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Sponsors & Collaborators

  • Shanghai Ming Ju Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weili Zhao, PhD · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

  • Depei Wu, PhD · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2024-01-21
Completion
2029-11-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093841 on ClinicalTrials.gov